August 30, 2021 7:40am
I’d be squeezing-out some profits from the weekly high flyers
Pre-open indications: SELLs into Strength: 3; BUYs: 3; Maintain SELL: 1
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Never leave an investor uninformed!
Dow futures are UP +0.04% (+15 points), S&P futures are UP +0.08% (+4 point) and NASDAQ futures are UP +0.11% (+17 points)
U.S. stock futures were trading safely and slowly higher in early morning trading on Monday
European markets traded slightly higher while U.K is closed for public holiday
Asia-Pacific markets rose, with Australian stocks recovering from an earlier slip as Covid cases in the country spike.
A positive start to the trading week in the final days of August reflects sentiment elsewhere, with U.S. stock futures steady in overnight trading on Sunday, and shares higher in Asia-Pacific. <CNBC>
Monday and Tuesday mark the last two trading days of the month; the S&P 500 is up +2.6%, the Dow was up +1.5% and the Nasdaq rose 1.5% in August.
The stock market rally had a strong week, hitting record highs even as Fed chief Powell said a bond taper is likely to start soon.
The Nasdaq and Russell 2000 had their best weekly gains in months.
Stocks could stay range-bound until the release of August’s jobs report on Friday.
Data Docket: the flash Markit (Dallas) manufacturing and services purchasing managers indexes (10 a.m.) are due for release after the market’s open, followed by existing home sales (10:30 a.m.).
If you didn’t know what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Friday’s evening’s recap: “: sector pops on rotation to biotech/healthcare” … https://www.regmedinvestors.com/articles/12070
- The Nasdaq closed UP +183.69 points (+1.23%);
- The IBB closed up +0.23% and XBI closed up +2.66%
- Sector volume was LOW with 5 of the 30-upside having higher than the 3-month average volume with very LOW volume of 1 of 2-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -2.51 points or -13.32% at 16.33
- Friday’s percentage (%) of the 30-upside were +0.53% (GBT) to +18.08% (BSTG) while the 2-downside -1.73% (BLFS) to -2.53% (VYGR);
- August - 11 positive and 9 negative close
- July: 6 positives, 1 holiday and 15 negative closes
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?
Biostage (BSTG) closed up again +$0.45 to $3.05 with 19,982 share traded after Thursday’s +$0.39 with 3,137 shares traded, Wednesday’s +$0.16 with 18,472 shares traded, Tuesday’s +$0.28 with 10,590 shares traded and last Monday’s +$0.68 to $1.89 with 38,354 shares traded.
Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial?
Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares? WHERE is the SEC?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
bluebird bio (BLUE) closed up +$0.20 on Friday after Thursday’s down -$0.28 and has a positive +$0.12 or +0.66% pre-market indication,
Editas Medicine (EDIT) closed up +$1.66 after Thursday’s down -$1.72, Wednesday’s +$0.87, Tuesday’s -0.64 and Monday’s $4.98 with a positive +$1.22 or +1.86% pre-market indication,
CRISPR Therapeutics (CRSP) closed up +$1.91 after Thursday’s down -$3.90, Wednesday’s -$0.66 and Tuesday’s +$1.44 and has a positive +$0.20 or +0.16% pre-market indication;
SELL into Strength:
Intellia Therapeutics (NTLA) closed up Friday +$5.52 after Thursday’s down -$3.99, Wednesday’s -$3.86 and Tuesday’s +$4.26 and has a positive +$4.00 or +2.50% pre-market indication;
Sage Therapeutics (SAGE) closed up +$1.92 and has a positive +$2.21 or +4.93% pre-market indication,
Vericel (VCEL) closed up +$2.98to $55.61, chart looks peaky and there was NO pre-open indication – make some profit with a +250.85% 52-week change,
The BOTTOM LINE: The month is almost over; a Labor Day holiday is on the horizon and I am prepared for a slow week and time-off – shoveling mulch.
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Investors should take short-term profits to cash-up for coming drifts!
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.